Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
4
×
life sciences
national blog main
boston
boston top stories
clinical trials
fda
alexion pharmaceuticals
alnylam pharmaceuticals
deals
drugs
national top stories
rna interference
alirocumab
amgen
amyotrophic lateral sclerosis (als)
autoimmune disorders
boehringer ingelheim
complement system
crispr
cystic fibrosis
cystic fibrosis foundation
dicerna pharamceuticals
evercore isi
evolocumab
generalized myasthenia gravis
gilead sciences
heart attack
hepatitis b
hepatitis b virus
hepatitis c
hereditary transthyretin amyloidosis
immune-mediated necrotizing myopathy
incivek
inclisiran
jeff leiden
joseph swartz
kayldeco
matt emmens
What
medicines
4
×
pharmaceuticals
4
×
drug
disease
pharma
alnylam
alternative
autoimmune
based
candidate
caught
causing
cf
cholesterol
crisis
cystic
data
deal
developer
dicerna
evidence
expensive
eye
fibrosis
force
gene
heart
helped
hepatitis
intended
jeff
lasting
lead
leiden
long
looms
lowering
medco
new
partner
Language
unset
unknown
Current search:
pharmaceuticals
×
medicines
×
" boston blog main "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms